Related Experiment Video
Updated: Jul 12, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin
Sergio Gallegos-Castorena1, Armando Martínez-Avalos, Alejandro Mohar-Betancourt
1Department of Pediatric Oncology, Hospital Infantil de Mexico Federico Gómez, Mexico, DF Mexico. galramos@prodigy.net.mx
Unlabelled:
Amifostine has emerged as a pancytoprotectant shown protection against nephrotoxicity, neurotoxicity and ototoxicity in preclinical studies.
Methods:
We designed a prospective comparative randomized trial to evaluate the cytoprotective effects of amifostine in patients with osteosarcoma receiving cisplatin and doxorrubicin. Patients were evaluated for renal, hearing and cardiac toxicity.
Results:
We included 28 patients, mean age was 11.6 years, five had metastatic disease. Fifteen patients received amifostine and 13 did not. 20% of patients receiving amifostine developed renal toxicity compared to 30% in the control group (p = 0.318). Grade 1 and 2 audiologic toxicity was present in 100% of the experimental group against 85% of the controls (p = 0.501). Grade 1 cardiac toxicity was present in 2 patients in the control group (p = 0.175). There were no statistical significant differences between the two groups for chemotherapy-related toxicity. Response to chemotherapy was significantly better in the amifostine group.
Conclusion:
amifostine did not reduce the ototoxicity and nephrotoxicity of our treatment regime. It was not well tolerated due to emesis. It is a selective cytoprotectant without reducing the effect of chemotherapy.
Related Concept Videos
Drug Toxicity: Risk factors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Pharmaceutical Poisoning: Treatment Strategies
Drug Toxicity: Overview
Pharmacokinetics in Pediatric Patients: Drug Metabolism
